105 related articles for article (PubMed ID: 30575377)
1. Discovery of Nonpeptide, Reversible HER1/HER2 Dual-Targeting Small-Molecule Inhibitors as Near-Infrared Fluorescent Probes for Efficient Tumor Detection, Diagnostic Imaging, and Drug Screening.
Liu S; Song W; Gao X; Su Y; Gao E; Gao Q
Anal Chem; 2019 Jan; 91(2):1507-1515. PubMed ID: 30575377
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
3. Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging.
Li C; Lin Q; Hu F; Bao R; Cai H; Gu Y
Biosens Bioelectron; 2022 Oct; 214():114503. PubMed ID: 35779413
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
6. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
7. HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.
Lyakhov I; Zielinski R; Kuban M; Kramer-Marek G; Fisher R; Chertov O; Bindu L; Capala J
Chembiochem; 2010 Feb; 11(3):345-50. PubMed ID: 20052708
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1.
Das D; Xie L; Wang J; Xu X; Zhang Z; Shi J; Le X; Hong J
Bioorg Med Chem Lett; 2019 Feb; 29(4):591-596. PubMed ID: 30600209
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore.
Pal R; Kang H; Choi HS; Kumar ATN
Clin Cancer Res; 2019 Nov; 25(22):6653-6661. PubMed ID: 31481509
[TBL] [Abstract][Full Text] [Related]
10. Zwitterionic near-infrared fluorophore-conjugated epidermal growth factor for fast, real-time, and target-cell-specific cancer imaging.
Kim H; Cho MH; Choi HS; Lee BI; Choi Y
Theranostics; 2019; 9(4):1085-1095. PubMed ID: 30867817
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
12. Dual-Labeled Near-Infrared/(99m)Tc Imaging Probes Using PAMAM-Coated Silica Nanoparticles for the Imaging of HER2-Expressing Cancer Cells.
Yamaguchi H; Tsuchimochi M; Hayama K; Kawase T; Tsubokawa N
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399687
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
[TBL] [Abstract][Full Text] [Related]
14. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
16. Shortwave-Infrared Fluorescent Molecular Imaging Probes Based on π-Conjugation Extended Indocyanine Green.
Swamy MMM; Murai Y; Monde K; Tsuboi S; Jin T
Bioconjug Chem; 2021 Aug; 32(8):1541-1547. PubMed ID: 34309379
[TBL] [Abstract][Full Text] [Related]
17. Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism.
Elseginy SA; Lazaro G; Nawwar GA; Amin KM; Hiscox S; Brancale A
Bioorg Med Chem Lett; 2015 Feb; 25(4):758-62. PubMed ID: 25619636
[TBL] [Abstract][Full Text] [Related]
18. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
19. Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer.
Buckle T; van Willigen DM; Spa SJ; Hensbergen AW; van der Wal S; de Korne CM; Welling MM; van der Poel HG; Hardwick JCH; van Leeuwen FWB
J Nucl Med; 2018 Jun; 59(6):986-992. PubMed ID: 29449447
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
